Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 151 to 160 of 2451 total matches.
Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
.1 Dupilumab is
also approved for several other indications, including
add-on treatment in patients ...
The subcutaneously injected interleukin-13 (IL-13)
antagonist tralokinumab-ldrm (Adbry – Leo) and
the oral Janus kinase (JAK) inhibitors abrocitinib
(Cibinqo – Pfizer) and upadacitinib (Rinvoq – Abbvie)
have been approved by the FDA for treatment of
moderate to severe atopic dermatitis.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):51-5 doi:10.58347/tml.2023.1673b | Show Introduction Hide Introduction
Atezolizumab (Tecentriq) for Alveolar Soft Part Sarcoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
of non-small
cell lung cancer, small cell lung cancer, hepatocellular
cancer, and melanoma (see Table 1 ...
Atezolizumab (Tecentriq – Genentech), an immune
checkpoint inhibitor, has been approved by the FDA
for treatment of unresectable or metastatic alveolar
soft part sarcoma (ASPS) in patients ≥2 years old. It
was previously approved for treatment of non-small
cell lung cancer, small cell lung cancer, hepatocellular
cancer, and melanoma (see Table 1). Atezolizumab is
the first drug to be approved in the US for treatment
of ASPS. ASPS is a rare disorder that affects mostly
adolescents and young adults; <1% of soft tissue
sarcomas are ASPS.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e56-7 doi:10.58347/tml.2023.1673d | Show Introduction Hide Introduction
Olutasidenib (Rezlidhia) for Acute Myeloid Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
isocitrate
dehydrogenase-1 (IDH1) inhibitor, has been
approved by the FDA for treatment of relapsed ...
Olutasidenib (Rezlidhia – Rigel), an oral isocitrate
dehydrogenase-1 (IDH1) inhibitor, has been
approved by the FDA for treatment of relapsed or
refractory acute myeloid leukemia (AML) in adults
with a susceptible IDH1 mutation. It is the second
drug that targets cancer metabolism to be approved
for this indication; ivosidenib (Tibsovo) was
approved in 2022.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e58-9 doi:10.58347/tml.2023.1673e | Show Introduction Hide Introduction
In Brief: Fam-trastuzumab deruxtecan (Enhertu) for Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
for treatment of HER2-positive breast cancer based on its rate and duration
of response,1 has been granted ...
Fam-trastuzumab deruxtecan-nxki (Enhertu – Daiichi
Sankyo/AstraZeneca), which received accelerated
approval by the FDA in 2019 for treatment of HER2-positive breast cancer based on its rate and duration
of response,1 has been granted regular approval for
treatment of adults with unresectable or metastatic
HER2-positive breast cancer who received a prior
anti-HER2-based regimen in the metastatic setting or
in the neoadjuvant or adjuvant setting and developed
recurrence during or within 6 months of completing
treatment.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e60-1 doi:10.58347/tml.2023.1673f | Show Introduction Hide Introduction
In Brief: A New Indication for Abemaciclib (Verzenio) (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
breast
cancer at high risk of recurrence.1 It was previously
approved for the same indication ...
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor
abemaciclib (Verzenio – Lilly) has been approved by
the FDA for use in combination with endocrine therapy
(tamoxifen or an aromatase inhibitor) for adjuvant
treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor
2 (HER2)-negative, node-positive, early breast
cancer at high risk of recurrence.1It was previously
approved for the same indication, but patients were
also required to have a Ki-67 score ≥20%. About
70% of all breast cancers are HR-positive and HER2-negative. Ki-67 is a...
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e62-3 doi:10.58347/tml.2023.1673g | Show Introduction Hide Introduction
Dostarlimab (Jemperli) for Endometrial Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
, estimated PFS at 24 months
was also significantly higher with dostarlimab than
with placebo (36.1% vs 18.1 ...
The FDA has granted regular approval to dostarlimabgxly
(Jemperli – GSK), an immune checkpoint
inhibitor, for treatment of adults with mismatch repair
deficient (dMMR) recurrent or advanced endometrial
cancer that has progressed on or following a prior
platinum-containing regimen in any setting and who
are not candidates for curative surgery or radiation.
Dostarlimab received accelerated approval in 2021
for treatment of adults with dMMR recurrent or
advanced endometrial cancer or nonendometrial
solid tumors that progressed on or following prior
treatment and who have no...
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e64-5 doi:10.58347/tml.2023.1673h | Show Introduction Hide Introduction
Drugs for Overactive Bladder
The Medical Letter on Drugs and Therapeutics • Mar 20, 2023 (Issue 1672)
of dietary irritants such as
alcohol and caffeine, should be tried first.1,2
ANTICHOLINERGIC DRUGS ...
In overactive bladder, involuntary bladder contractions
due to detrusor overactivity result in urinary
urgency, frequency, nocturia, and incontinence.
The prevalence of the disorder increases with age.
Nonpharmacologic treatment, including bladder
training, urge suppression, pelvic floor muscle
exercises, constipation management, modification of
fluid intake, and avoidance of dietary irritants such as
alcohol and caffeine, should be tried first.
Med Lett Drugs Ther. 2023 Mar 20;65(1672):41-5 doi:10.58347/tml.2023.1672a | Show Introduction Hide Introduction
A Dexamethasone Ophthalmic Insert (Dextenza) for Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Mar 20, 2023 (Issue 1672)
of allergic conjunctivitis was based
on the results of 3 randomized, double-masked
trials (1 published; 2 ...
The FDA has approved Dextenza (Ocular Therapeutix),
a dexamethasone ophthalmic insert, for
treatment of ocular itching associated with allergic
conjunctivitis. Dextenza was approved earlier for
treatment of ocular inflammation and pain following
ophthalmic surgery.
Med Lett Drugs Ther. 2023 Mar 20;65(1672):45-6 doi:10.58347/tml.2023.1672b | Show Introduction Hide Introduction
Terlipressin (Terlivaz) for Hepatorenal Syndrome
The Medical Letter on Drugs and Therapeutics • Mar 20, 2023 (Issue 1672)
for years.1,2
Pronunciation Key
Terlipressin: ter″ li pres′ in Terlivaz: ter li vaz
HEPATORENAL SYNDROME ...
The FDA has approved the intravenously administered
synthetic vasopressin analog terlipressin (Terlivaz –
Mallinckrodt) to improve kidney function in adults
with hepatorenal syndrome (HRS) and a rapid decline
in kidney function. Terlipressin is the first drug to be
approved for this indication in the US; it has been
available in Europe and elsewhere for year
Med Lett Drugs Ther. 2023 Mar 20;65(1672):46-8 doi:10.58347/tml.2023.1672c | Show Introduction Hide Introduction
In Brief: Off-Label Amitriptyline for Insomnia
The Medical Letter on Drugs and Therapeutics • Mar 20, 2023 (Issue 1672)
are effective
in treating insomnia not associated with depression.1
We received a comment from a reader who ...
In our article on Drugs for Chronic Insomnia, we said
there is little evidence that antidepressants such as
trazodone, mirtazapine, or amitriptyline are effective
in treating insomnia not associated with depression.
We received a comment from a reader who has
prescribed the tricyclic antidepressant amitriptyline
for insomnia, particularly for patients with headache
disorders, and finds that most patients are satisfied
with the treatment.
Med Lett Drugs Ther. 2023 Mar 20;65(1672):48 doi:10.58347/tml.2023.1672d | Show Introduction Hide Introduction